|
Preventing complications and treating symptoms of diabetic peripheral neuropathy |
Dy SM, Bennett WL, Sharma R, Zhang A, Waldfogel JM, Nesbit SA, Yeh H, Chelladurai Y, Feldman D, Wilson LM, Robinson KA |
|
|
Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dy SM, Bennett WL, Sharma R, Zhang A, Waldfogel JM, Nesbit SA, Yeh H, Chelladurai Y, Feldman D, Wilson LM, Robinson KA. Preventing complications and treating symptoms of diabetic peripheral neuropathy. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 187. 2017 Authors' objectives To assess benefits and harms of interventions for preventing diabetic peripheral neuropathy (DPN) complications and treatment of DPN symptoms. Authors' conclusions For prevention of complications, intensive glycemic control is more effective than standard control for prevention of amputation, and home monitoring of foot skin temperature, therapeutic footwear, and integrated interventions are effective for preventing incidence and/or recurrence of foot ulcers. For reducing pain, the only class with moderate strength of evidence was serotonin-noradrenaline reuptake inhibitors; pregabalin and oxcarbazepine, atypical opioids, botulinum toxin, alpha-lipoic acid and spinal cord stimulation are more effective than placebo but with low SOE. However, studies were generally short term with unclear risk of bias, we could not draw conclusions for quality of life, all oral drugs had significant side effects, opioids have significant long-term risks including abuse, and spinal cord stimulation has risks of serious complications. Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov AccessionNumber 32017000247 Date abstract record published 09/05/2017 |
|
|
|